EyePoint, Inc. (EYPT) Stock Analysis
A live, multi-source view of EyePoint, Inc. (EYPT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare · Industry: Biotechnology · United States · 214 employees · eyepoint.bio
Key statistics · as of 2026-09-05
As of 2026-09-05, EyePoint, Inc. (EYPT) had a market capitalization of $384.0M (forward -1.7) and a beta of 1.64; the shares traded in a 52-week range of $3.95 – $19.11 (-66.4% over the year).
- Market cap
- $384.0M
- Enterprise value
- $407.2M
- Forward P/E
- -1.7
- Price / book
- 11.57
- EPS (trailing)
- $-3.75
- EPS (forward)
- $-2.76
- Payout ratio
- 0.0%
- 52-week range
- $3.95 – $19.11
- 52-week change
- -66.4%
- Beta
- 1.64
- Average volume
- 3.3M
- Shares outstanding
- 83.8M
- Short % of float
- 22.50%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, EyePoint, Inc. (EYPT) last closed at $4.58 (the last completed close before that scan).
Technicals at the scan: RSI 30 (oversold territory), price -35.6% versus its 20-day average, 20-day versus 50-day average spread -34.0%, MACD histogram -0.01.
Sentiment inputs: 57% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 65/100.
Next scheduled company event: in 57 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of EYPT; corporate insiders filed 1 buy and 0 sells (1 filer, latest disclosure 2026-08-18). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Karen L. Zaderej (1B/0S). Who is trading what
RapidTradeView pick record
EYPT has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls EyePoint, Inc. (EYPT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell EYPT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.